Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.51 |
| ▸ | HTR2A | P28223 | 6/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151177 | 0.77 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6152457 | 0.75 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6151910 | 0.70 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6151938 | 0.70 | HTR2A (0.55) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL9121785 | 0.69 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL18648038 | 0.68 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL5193554 | 0.65 | TDP1 (0.65) | SMN1; SMN2ALDH1A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL6612924 | 0.65 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL7527306 | 0.64 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL8103794 | 0.63 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029972-A1 | Combination treatment for depression | HOWARD HARRY R (US) | 2004-02-12 | — | — | US | claimed |
| US-20020183306-A1 | Combination treatment for sleep disorders including sleep apnea | PFIZER INC. | 2002-12-05 | — | — | US | claimed |
| EP-1262197-A2 | Combination treatment for sleep disorders including sleep apnea | Pfizer Products Inc. (US) | 2002-12-04 | — | — | EP | claimed |
| US-20020165217-A1 | Combination treatment for anxiety and depression | PFIZER INC. | 2002-11-07 | — | — | US | claimed |
| US-20020123490-A1 | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis | PFIZER INC. | 2002-09-05 | — | — | US | claimed |
| US-6436938-B1 | ADMINISTERING A SIGMA RECEPTOR LIGAND IN COMBINATION WITH AN ANTIDEPRESSANT AGENT; ESPECIALLY FOR REFRACTORY DEPRESSION | PFIZER INC. | 2002-08-20 | — | — | US | claimed |
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | PFIZER PRODUCTS INC. | 2002-08-08 | — | — | US | claimed |
| US-20020099045-A1 | Combination treatment for depression | PFIZER PRODUCTS INC. | 2002-07-25 | — | — | US | claimed |
| EP-1220831-B1 | BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | PFIZER PROD INC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040162316-A1 | Combination treatment for alcoholism and alcohol dependence | PFIZER INC | 2004-08-19 | — | — | US | disclosed |
| EP-1238676-B1 | Combination of a serotonin reuptake inhibitor and an atypical antipsychotic for use in depression, obsessive compulsive disorder and psychosis | PFIZER PROD INC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20040029972-A1 | Combination treatment for depression | HOWARD HARRY R (US) | 2004-02-12 | — | — | US | disclosed |
| US-6596741-B2 | Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders. | PFIZER INC | 2003-07-22 | — | — | US | disclosed |
| US-20030130322-A1 | Biaryl ether derivative as opiod antagonist | PFIZER INC. | 2003-07-10 | — | — | US | disclosed |
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | PFIZER PRODUCTS INC. | 2002-08-08 | — | — | US | disclosed |
| US-20020099045-A1 | Combination treatment for depression | PFIZER PRODUCTS INC. | 2002-07-25 | — | — | US | disclosed |
| EP-1224930-A1 | Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression | Pfizer Products Inc. (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1220831-A1 | BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | Pfizer Products Inc. (US) | 2002-07-10 | — | — | EP | disclosed |
| US-6410736-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-06-25 | — | — | US | disclosed |
| WO-2001027068-A1 | BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130322-A1 | Biaryl ether derivative as opiod antagonist | OPRM1, OPRD1, OPRK1 | SLC6A4 40/4885SLC6A2 11/4885SLC6A3 31/4885 |
| US-20020165217-A1 | Combination treatment for anxiety and depression | GABRA1, GABRA2, GABRA5 | SLC6A4 40/4885SLC6A2 37/4885SLC6A3 67/4885 |
| US-20020183306-A1 | Combination treatment for sleep disorders including sleep apnea | HTR1A, HTR2A, ADRA2A | SLC6A4 30/4885SLC6A2 22/4885SLC6A3 80/4885 |
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | HTR3A, HTR3E, HTR4 | SLC6A4 19/4885SLC6A2 49/4885SLC6A3 34/4885 |
| US-20040029972-A1 | Combination treatment for depression | HTR3A, HTR5A, HTR6 | SLC6A4 14/4885SLC6A2 29/4885SLC6A3 22/4885 |
| US-20040162316-A1 | Combination treatment for alcoholism and alcohol dependence | OPRM1, SLC6A2, OPRK1 | SLC6A4 13/4885SLC6A2 2/4885SLC6A3 10/4885 |
| US-20020123490-A1 | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis | SLC6A3, OXTR, OPRD1 | SLC6A4 5/4885SLC6A2 12/4885SLC6A3 1/4885 |
| US-20020099045-A1 | Combination treatment for depression | HTR5A, HTR1A, OPRL1 | SLC6A4 11/4885SLC6A2 18/4885SLC6A3 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.